AUSTIN, TX and DURHAM, NC, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present a corporate update and participate in one-on-one meetings at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, C ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. (Exact name of registrant as specified in its charter) Delaware 81-2575858 (State or other jurisdic ...

Exhibit 99.1 Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights – Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND filing expected in Q3'2025 – – Cash balance of approximately $90M as of September 30, 2024; expected to fund operations into 2027 – AUSTIN, TX and DURHAM, NC, November 14, 2024 – Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a biotechnology company pioneering the development of novel therapeutics tar ...

A downtrend has been apparent in Shattuck Labs, Inc. (STTK) lately with too much selling pressure. The stock has declined 64.2% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. How to Determine if a Stock is Oversold We use Relative Strength Index (RSI), one of the most commonly used technical indic ...

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (NASDAQ: STTK). Investors who purchased Shattuck securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/STTK. Investigation Details On October 1, 2024, Shattuck issued a press release announcing the discontinuation of its lea ...

Shattuck Labs, Inc. (STTK) has been on a downward spiral lately with significant selling pressure. After declining 69% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether ...

Shattuck Labs (STTK) announced its decision to discontinue the development of its pipeline candidate SL172154, which was being developed for acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS), types of blood cancer, as part of its strategic pipeline prioritization efforts. This disappointed investors as SL-172154 was the only clinical-stage candidate in Shattuck's pipeline. Following the news, the stock plummeted 45% on Tuesday and lost another 3.7% during the after-market hours ...

– Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvement in median overall survival compared to azacitidine monotherapy benchmarks; further development of SL-172154 discontinued – – Prioritization to focus on SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A, intended for clinical development in inflammatory bowel disease (IBD); IND filin ...

Shattuck Labs, Inc. (STTK) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.50 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -2.44%. A quarter ago, it was expected that this company would post a loss of $0.47 per share when it actually produced a loss of $0.37, delivering a surprise of 21.28%. Over the last four quarters, the company has su ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. (Exact name of registrant as specified in its charter) Delaware 81-2575858 (State or other jurisdiction ...